Corcept Therapeutics Incorporated (NASDAQ:CORT) received a $30.00 price objective from research analysts at Piper Jaffray Companies in a report released on Tuesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Piper Jaffray Companies’ price target suggests a potential upside of 52.36% from the company’s previous close.
Other equities research analysts have also issued research reports about the stock. BidaskClub upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 18th. Zacks Investment Research lowered shares of Corcept Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Ladenburg Thalmann Financial Services set a $20.00 price target on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Finally, Stifel Nicolaus assumed coverage on shares of Corcept Therapeutics in a research note on Thursday, August 31st. They set a “buy” rating and a $20.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Corcept Therapeutics has a consensus rating of “Buy” and an average price target of $17.17.
Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.02. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The company had revenue of $35.56 million during the quarter, compared to analyst estimates of $31.37 million. During the same quarter last year, the business posted $0.01 EPS. Corcept Therapeutics’s quarterly revenue was up 80.3% compared to the same quarter last year.
Institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. purchased a new position in Corcept Therapeutics in the 3rd quarter valued at approximately $108,000. BNP Paribas Arbitrage SA grew its position in shares of Corcept Therapeutics by 2,942.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,707 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 9,388 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Corcept Therapeutics by 52.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 3,390 shares in the last quarter. Sand Hill Global Advisors LLC purchased a new position in shares of Corcept Therapeutics during the 2nd quarter valued at $118,000. Finally, Jasper Ridge Partners L.P. purchased a new position in shares of Corcept Therapeutics during the 2nd quarter valued at $118,000. Institutional investors and hedge funds own 62.22% of the company’s stock.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
What are top analysts saying about Corcept Therapeutics Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corcept Therapeutics Incorporated and related companies.